Oligonucleotide CDMO Market to Reach $11.14 Billion by 2031

The global market for oligonucleotide contract development and manufacturing organizations (CDMOs) is forecast to reach $11.14 billion by 2031. This market was valued at $3.88 billion in 2026, indicating a substantial growth trajectory.

The expansion is primarily driven by increasing investments and demand for oligonucleotide-based therapies, particularly in areas such as oncology, rare diseases, and infectious diseases. Advancements in technology and the identification of new therapeutic applications are also contributing to the sector's growth.

According to a report by MarketsandMarkets™, the market is expected to grow at a compound annual growth rate (CAGR) of 23.5% during the forecast period. This robust growth underscores the rising significance of oligonucleotides in drug development and treatment.

Further growth is anticipated due to government funding initiatives and strategic partnerships between pharmaceutical companies and CDMOs. Many firms are expanding their manufacturing capabilities to meet the escalating demand for these specialized services.